Skip to main content
OLYMY logo

Olympus Corporation (OLYMY) Stock Price & Analysis

Olympus Corporation (OLYMY) — price $11.44 (+2.23%), as of the Nov 19, 2026 trading session; market cap $12.2B. Expected results Feb 12, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$11.44 +$0.25 (+2.23%) Market Cap $12.2B

Olympus Corporation · OLYMY · Healthcare · Medical - Devices

Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SNN · Smith & Nephew plc · 84 /100
  • PEN · Penumbra, Inc. · 92 /100
  • ALGN · Align Technology, Inc. · 83 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.44
Change on the day+2.23%
52-week range$8.08–$13.72
Market capitalisation$12.2B—
Price / earnings (trailing)21.38
Shares traded on the day3.6K
Beta (volatility vs the S&P 500)0.21
Dividends per share (last 12 months)$0.16
Dividend yield (last 12 months)1.46%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $8.09, high $14, latest $11. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $14 $8.09 high $14 Feb 13, 2026 · Earnings results · reported below the recorded estimate · close $111May 12, 2026 · Earnings results · reported above the recorded estimate · close $112Aug 7, 2026 · Earnings results · reported above the recorded estimate · close $133Nov 10, 2026 · Earnings results · reported above the recorded estimate · close $114 Oct 17, 2025 Nov 19, 2026 · $11 $12Oct 17, 2025$12Oct 31, 2025$14Nov 14, 2025$13Nov 28, 2025$13Dec 12, 2025$13Dec 26, 2025$13Jan 9, 2026$12Jan 23, 2026$12Feb 6, 2026$9.52Feb 20, 2026$8.38Mar 6, 2026$8.39Mar 20, 2026$9.76Apr 2, 2026$10Apr 17, 2026$9.96May 1, 2026$11May 15, 2026$11May 29, 2026$11Jun 12, 2026$10Jun 26, 2026$11Jul 10, 2026$11Jul 24, 2026$13Aug 7, 2026$14Aug 21, 2026$13Sep 4, 2026$13Sep 18, 2026$12Oct 2, 2026$11Oct 16, 2026$11Oct 30, 2026$11Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Olympus (OLYMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Olympus (OLYMY), and what does it report?

Short answer

Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Healthcare / Medical Devices SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 28,138 people. In Q1 FY2027 it reported revenue of ¥239.81B and net income of ¥19.05B. The market values it at $12.2B.

2 · Latest results

What do the latest results show for Olympus (OLYMY)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of ¥239.81B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.68B Nov 10, 2026
Latest report · revenue estimate
$1.69B Nov 10, 2026
Latest report · revenue vs estimate
Below estimate Nov 10, 2026
Latest report · EPS vs estimate
Above estimate Nov 10, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 10, 2026$1.68B$1.69B$0.1941$0.1401
Aug 7, 2026$1.51B$1.42B$0.1117$0.0536
May 12, 2026$1.87B$1.78B$0.1422$0.0485
Feb 13, 2026$1.70B$1.68B$0.0839$0.1490
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027¥239.81B¥19.05B¥17.49 (diluted)
Q4 FY2026¥288.38B¥24.24B¥21.45 (diluted)
Q3 FY2026¥261.93B¥14.22B¥12.88 (diluted)
Q2 FY2026¥247.84B¥20.20B¥18.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Olympus (OLYMY)?

Short answer · as of

The distress and quality screens read Altman Z 3.17 · Piotroski F 7. Trailing ratios: ROE 11.8% · ROA 6.0% · current ratio 1.67 · earnings yield 4.8% · free-cash-flow yield 4.7%.

4 · What to check next?

What should you watch next at Olympus (OLYMY)?

Short answer · as of

The next earnings report is expected on Feb 12, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held OLYMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported OLYMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

OLYMY Healthcare Stock FAQ

Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

Why is Olympus more than an endoscope manufacturer?

Beyond gastrointestinal visualization, Olympus supplies therapeutic, respiratory, urological, surgical, gynecological, and ear, nose, and throat products. Software, computer-assisted diagnosis, operating-room integration, reprocessing, and repair broaden the business further.

What is the OLYMY stock price today?

The last price recorded for Olympus Corporation (OLYMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Does OLYMY pay a dividend?

Yes. The dividend yield of Olympus Corporation (OLYMY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 31 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: Why is Olympus more than an endoscope manufacturer?: Business description; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.